Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR2554 food effect study in healthy adults
NCT05592262Phase 1Completed
- Sponsor
- Hengrui
- Start
- Nov 2022
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of zeprumetostat in cancer and lymphoma (2 arms), sponsored by Hengrui. Primary endpoints: Maximum Plasma Concentration, Area Under the Curve from time 0 to last measurable concentration and 1 more. Started Nov 2022; status: completed.
02
Drugs
zeprumetostat
03
Conditions
cancerlymphoma
Beyond the preview
Go deeper on NCT05592262.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05592262.